Good morning, everyone, and how are you today? We are doing just fine, thank you, despite darkening skies hovering over the Pharmalot campus. Our spirits remain sunny thanks to the amusing official mascot, who is running up and down the stairs at a dizzying pace, and a few cups of delicious stimulation. Our choice today is maple bourbon, for those tracking this sort of thing. All of which brings us to say that it is time to get cracking. So here are a few items of interest. We hope your day goes well and, of course, do stay safe. …

Hundreds of millions of cloth face masks shipped to U.S. agencies, nonprofit organizations, and private companies by the Trump administration appear to have been allocated in a haphazard fashion, raising questions about inequitable distribution in the effort to beat back the Covid-19 pandemic, STAT reports. Under the $675 million program, businesses and other entities were provided with supplies of the free, reusable masks that in some cases far exceeded their needs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy